The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites.
FDA News Releases published a clinical update in Research Highlights on 03 Mar 2026. The item focuses on FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Open the detail page to review the full original feed content.